alexa Viral Kinetics of the Y448H HCV NS5B Polymerase Mutant in Patients Treated with the HCV Inhibitor Tegobuvir (GS-9190) | OMICS International | Abstract
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Viral Kinetics of the Y448H HCV NS5B Polymerase Mutant in Patients Treated with the HCV Inhibitor Tegobuvir (GS-9190)

Karin S Ku*, Derrick D Goodman, Andrew S Bae, Michael D Miller, Hongmei Mo and Evguenia S Svarovskaia

Gilead Sciences Inc., Foster City, CA USA

*Corresponding Author:
Karin S Ku
Gilead Sciences, Inc., 333 Lakeside Drive
Foster City, CA 94404, USA
Tel: 650-522-6163
Fax: 650-522-5890
E-mail: [email protected]

Received Date: July 11, 2013; Accepted Date: September 01, 2013; Published Date: September 03, 2013

Citation: Ku KS, Goodman DD, Bae AS, Miller MD, Mo H, et al. (2013) Viral Kinetics of the Y448H HCV NS5B Polymerase Mutant in Patients Treated with the HCV Inhibitor Tegobuvir (GS-9190). J Antivir Antiretrovir 5:101-107. doi: 10.4172/jaa.1000071

Copyright: © 2013 Ku KS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Tegobuvir (GS‑9190) is a novel hepatitis C virus (HCV) non‑nucleoside NS5B polymerase inhibitor that effectively inhibits HCV replication in HCV-infected genotype (GT) 1 patients. The NS5B Y448H mutation was the most frequent mutation selected in patients receiving tegobuvir. In this study, we employed allele-specific PCR (AS-PCR) to monitor Y448H kinetics and estimate the pre-existing Y448H levels in HCV-infected patients and replicon cells. Y448H ASPCR was developed with a 0.5% assay cut-off to test replicon cells treated with tegobuvir and samples from HCVinfected GT 1 patients who received 8-days of tegobuvir monotherapy. By population sequencing, Y448H was not detected at baseline in serum samples from any of the 65 patients enrolled in the study. Using the more sensitive AS-PCR, Y448H was assessed in 62/65 patients at baseline and detected at >0.5% in 5/62 patients. Longitudinal patient samples were tested to monitor the Y448H replication kinetics during the 8-day tegobuvir monotherapy. The replication kinetics of the mutant virus were used to extrapolate a median baseline Y448H frequency of 0.025% (-3.6 log10). For the in vitro selection of GT 1b tegobuvir-treated replicon cells, pre-existing Y448H levels were similarly estimated at 0.015% (-3.8 log10). Pre-existing levels of the drug-resistant variant Y448H suggest a maximal 3.6 log10 HCV RNA reduction during monotherapy with optimal doses of NS5B non-nucleoside polymerase inhibitors that select for Y448H. These results aid in the prediction of the patient viral response and study designs to best achieve maximal antiviral response.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7